CAL-101

idelalisib · Gilead Sciences

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for CAL-101, covering 2012-08-31 to 2012-08-31. Get the full timeline:

Most recent: Clinical Trial Update: Dose Escalation Study of CAL-101 in Select Relapsed or Refractory Hematologic Malignancies [Phase 1]